ReviewSmall (Weinheim an der Bergstrasse, Germany)2019
Cancer Modeling-on-a-Chip with Future Artificial Intelligence Integration.
Review in Small (Weinheim an der Bergstrasse, Germany), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 107 citations in OpenAlex.
- Concerns and challenges in clinics-guided nanovaccines design and applications.Acta pharmaceutica Sinica. B · 2026Review
- Human Multi-Organ-on-a-Chip Platforms for Next-Generation Drug Delivery Strategies.Theranostics · 2026Review
- Functional material probes and advanced technologies in organ-on-a-chip characterization.Theranostics · 2026Review
- Intelligent design of tumor microenvironment-responsive Adeno-associated virus vectors: overcoming delivery barriers and enabling precision therapy.Medical oncology (Northwood, London, England) · 2025Review
- Bioengineering 3D Pancreatic Cancer Models with Fibrotic Stroma for In Vitro Cancer Modeling.Micromachines · 2025Review
- Vascularized Tumor-on-a-Chip Model as a Platform for Studying Tumor-Microenvironment-Drug Interaction.Macromolecular bioscience · 2025Review
- Exploring bone-tumor interactions through 3DJournal of bone oncology · 2025Review
- Engineering in vitro vascular microsystems.Microsystems & nanoengineering · 2025Review
- Tumor microenvironment: recent advances in understanding and its role in modulating cancer therapies.Medical oncology (Northwood, London, England) · 2025Review
- Review
- Targeted Cancer Therapy-on-A-Chip.Advanced healthcare materials · 2024Review
- The progressive trend of modeling and drug screening systems of breast cancer bone metastasis.Journal of biological engineering · 2024Review
- Micro-engineering and nano-engineering approaches to investigate tumour ecosystems.Nature reviews. Cancer · 2023Review
- On-chip modeling of tumor evolution: Advances, challenges and opportunities.Materials today. Bio · 2023Review
- Transformative Materials to Create 3D Functional Human Tissue Models In Vitro in a Reproducible Manner.Advanced healthcare materials · 2023Article
- Multifunctional nanostructures: Intelligent design to overcome biological barriers.Materials today. Bio · 2023Review
- Spatiotemporal dissection of tumor microenvironment via in situ sensing and monitoring in tumor-on-a-chip.Biosensors & bioelectronics · 2023Article
- The Synergy between Deep Learning and Organs-on-Chips for High-Throughput Drug Screening: A Review.Biosensors · 2023Review
- Engineering organ-on-a-chip systems to model viral infections.Biofabrication · 2023Review
- Spheroid Engineering in Microfluidic Devices.ACS omega · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
Abstract
Cancer is one of the leading causes of death worldwide, despite the large efforts to improve the understanding of cancer biology and development of treatments. The attempts to improve cancer treatment are limited by the complexity of the local milieu in which cancer cells exist. The tumor microenvironment (TME) consists of a diverse population of tumor cells and stromal cells with immune constituents, microvasculature, extracellular matrix components, and gradients of oxygen, nutrients, and growth factors. The TME is not recapitulated in traditional models used in cancer investigation, limiting the translation of preliminary findings to clinical practice. Advances in 3D cell culture, tissue engineering, and microfluidics have led to the development of "cancer-on-a-chip" platforms that expand the ability to model the TME in vitro and allow for high-throughput analysis. The advances in the development of cancer-on-a-chip platforms, implications for drug development, challenges to leveraging this technology for improved cancer treatment, and future integration with artificial intelligence for improved predictive drug screening models are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.